- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 51,94 | +0,15 % | AKTIEN IM FOKUS: Chemiewerte unter Druck - Analystin befürchtet langen Abschwung | FRANKFURT (dpa-AFX) - Ein skeptischer Branchenkommentar der Deutschen Bank hat am Mittwoch bei Chemiewerten Spuren hinterlassen. Allen voran galt dies für die Aktien von Lanxess, die wegen einer gestrichenen... ► Artikel lesen | |
| GENMAB | 247,20 | -0,24 % | H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB) | ||
| ARBUTUS BIOPHARMA | 4,182 | +1,16 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| VERICEL | 30,200 | -0,66 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin | HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,570 | 0,00 % | Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value | BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,742 | +0,11 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| MUSTGROW BIOLOGICS | 0,393 | +0,51 % | MustGrow Biologics Corp.: MustGrow Announces Grant of RSUs and DSUs | Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors... ► Artikel lesen | |
| REGENXBIO | 11,400 | +2,70 % | Exosomen statt Viren: Warum NurExone, Regenxbio und Voyager den Markt für Nerventherapien verändern könnten | ||
| AKEBIA | 1,894 | -0,94 % | Morning Market Movers: Cambium Networks, Stride, Inc., Varonis Systems, Akebia Therapeutics See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 9,000 | +1,69 % | Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call | ||
| FENNEC PHARMACEUTICALS | 6,950 | -2,80 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update | ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | AbbVie wins $56M royalty award from Revance in Botox patent infringement case | ||
| CORVUS PHARMACEUTICALS | 7,140 | +3,03 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis | SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,700 | -0,74 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants |
BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,003 (-0,31 %) liegt der Kurs bei 0,973 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.